UY35650A - HETEROCYCLIC COMPOUND - Google Patents

HETEROCYCLIC COMPOUND

Info

Publication number
UY35650A
UY35650A UY35650A UY35650A UY35650A UY 35650 A UY35650 A UY 35650A UY 35650 A UY35650 A UY 35650A UY 35650 A UY35650 A UY 35650A UY 35650 A UY35650 A UY 35650A
Authority
UY
Uruguay
Prior art keywords
heterocyclic compound
compound
prophylaxis
obesity
symbol
Prior art date
Application number
UY35650A
Other languages
Spanish (es)
Inventor
Ikoma Minoru
Aida Jumpei
Igawa Hideyuki
Takahashi Masashi
Kakegawa Keiko
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY35650A publication Critical patent/UY35650A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Se proporciona un compuesto que tiene una acción antagonista del receptor de la hormona concentradora de melanina y que es útil como agente para la p rofilaxis o el tratamiento de la obesidad y similares. Un compuesto representado por la fórmula (I) : en donde cada símbolo está de acuerdo con lo definido en la memoria descriptiva, o una sal del mismo.A compound is provided that has an antagonistic action of the melanin concentrating hormone receptor and that is useful as an agent for prophylaxis or the treatment of obesity and the like. A compound represented by the formula (I): where each symbol is in accordance with what is defined in the specification, or a salt thereof.

UY35650A 2013-07-09 2014-07-08 HETEROCYCLIC COMPOUND UY35650A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013143940 2013-07-09

Publications (1)

Publication Number Publication Date
UY35650A true UY35650A (en) 2015-02-27

Family

ID=51220851

Family Applications (1)

Application Number Title Priority Date Filing Date
UY35650A UY35650A (en) 2013-07-09 2014-07-08 HETEROCYCLIC COMPOUND

Country Status (9)

Country Link
US (1) US9199963B2 (en)
EP (1) EP3019487A1 (en)
JP (1) JP2016523809A (en)
CN (1) CN105358544A (en)
AR (1) AR096848A1 (en)
CA (1) CA2917490A1 (en)
TW (1) TW201536767A (en)
UY (1) UY35650A (en)
WO (1) WO2015005489A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013105676A1 (en) * 2012-01-12 2013-07-18 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as mch receptor antagonists
US9440987B2 (en) * 2012-05-10 2016-09-13 Takeda Pharmaceutical Company Limited Aromatic ring compound
CR20220294A (en) 2019-12-20 2022-08-03 Bayer Ag Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof
HUP2200222A1 (en) 2022-06-17 2023-12-28 Richter Gedeon Nyrt Mchr1 antagonists for the treatment of prader-willi syndrome

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849708A (en) 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
EP0862562B1 (en) 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
EP0848060A3 (en) 1996-12-11 2000-02-02 Smithkline Beecham Corporation Novel human 11CB splice variant
PT1009808E (en) 1997-09-05 2013-01-29 Genzyme Corp Methods for generating high titer helper-free preparations of recombinant aav vectors
EP1042498A4 (en) 1997-12-03 2003-05-07 Smithkline Beecham Corp A method of finding agonist and antagonist to human 11cb splice variant
WO2000049170A1 (en) 1999-02-18 2000-08-24 Smithkline Beecham Corporation MURINE 11cby RECEPTOR
AR035016A1 (en) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd COMPOSITION OF AZOL PROMOTER OF PRODUCTION / SECRETION OF NEUROTROFINE, COMPOSITE PRODROGA OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THE SAME TO PREPARE THIS LAST.
WO2001082925A1 (en) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonists
WO2002006234A1 (en) 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Sulfone derivatives, process for their production and use thereof
CA2460594A1 (en) 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Mch receptor antagonists
US7101845B2 (en) 2002-01-31 2006-09-05 Joslin Diabetes Center, Inc. Methods of modulating β cell function
PT1490064E (en) 2002-02-14 2009-12-28 Pharmacia Corp Substituted pyridinones as modulators of p38 map kinase
WO2004028453A2 (en) 2002-09-25 2004-04-08 Neurogen Corporation Methods for preventing and treating obesity in patients with mc4 receptor mutations
CN1731994A (en) 2002-11-01 2006-02-08 武田药品工业株式会社 Prophylactic and therapeutic agent for neuropathy
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
EP1564213A4 (en) 2002-11-22 2009-05-27 Takeda Pharmaceutical Imidazole derivative, process for producing the same, and use
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
CL2004002050A1 (en) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B COMPOUNDS DERIVED FROM REPLACED PIRIDINONES; ITS USE IN THE TREATMENT OF AFFECTIONS CAUSED OR EXACTED BY ACTIVITY P38 MAP KINASA AND / OR NON-REGULATED TNF, SUCH AS INFLAMMATIONS, TUMORS, AIDS AND OTHERS.
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
WO2005040824A2 (en) 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
US7820673B2 (en) 2003-12-17 2010-10-26 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
TW200523247A (en) 2003-12-25 2005-07-16 Takeda Pharmaceutical 3-(4-benzyloxyphenyl) propanoic acid derivatives
JP4855777B2 (en) 2003-12-26 2012-01-18 武田薬品工業株式会社 Phenylpropanoic acid derivatives
EP1726580A4 (en) 2004-03-15 2008-02-13 Takeda Pharmaceutical Aminophenylpropanoic acid derivative
JP4859665B2 (en) 2004-03-30 2012-01-25 武田薬品工業株式会社 Alkoxyphenylpropanoic acid derivatives
TWI396686B (en) 2004-05-21 2013-05-21 Takeda Pharmaceutical Cyclic amide derivative, and its production and use
JPWO2006104136A1 (en) 2005-03-29 2008-09-11 萬有製薬株式会社 Non-alcoholic fatty liver disease therapeutic agent and method for screening candidate compounds for treatment or prevention of non-alcoholic fatty liver disease
JP5094394B2 (en) 2005-04-20 2012-12-12 武田薬品工業株式会社 Fused heterocyclic compounds
JPWO2007013694A1 (en) 2005-07-29 2009-02-12 武田薬品工業株式会社 Phenoxyalkanoic acid compound
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
BRPI0615150A2 (en) 2005-08-10 2017-06-20 Takeda Pharmaceuticals Co agent for the prophylaxis or treatment of diabetes, insulin sensitizer, compound, prodrug, pharmaceutical agent, and use of the compound or a salt thereof or a prodrug thereof
JP2007063225A (en) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd Imidazopyridine compound
CA2621470A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
WO2008001931A2 (en) 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Fused cyclic compounds
WO2008047821A1 (en) 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US8410087B2 (en) 2006-10-19 2013-04-02 Takeda Pharmaceutical Company Limited Indole compound
KR20090127867A (en) 2006-12-05 2009-12-14 네이셔널 치아오 텅 유니버시티 Indazole compounds
CN101679348A (en) * 2007-01-10 2010-03-24 阿尔巴尼分子研究公司 5-pyridinone substituted indazoles
KR20090097214A (en) 2007-01-10 2009-09-15 알바니 몰레큘라 리써치, 인크. 5-furopyridinone substituted indazoles
US20100016396A1 (en) 2007-01-29 2010-01-21 Hiroshi Imoto Pyrazole compound
AU2008215490A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of PPAR-gamma
WO2008136428A1 (en) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
US20110301155A1 (en) 2007-06-19 2011-12-08 Tsuneo Yasuma Indazole compounds for activating glucokinase
US20120316200A1 (en) * 2010-04-12 2012-12-13 Merck Sharp & Dohme Corp. Pyridone derivatives
WO2011127643A1 (en) 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. Pyridone derivatives
WO2013105676A1 (en) 2012-01-12 2013-07-18 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as mch receptor antagonists

Also Published As

Publication number Publication date
WO2015005489A1 (en) 2015-01-15
JP2016523809A (en) 2016-08-12
AR096848A1 (en) 2016-02-03
CN105358544A (en) 2016-02-24
US9199963B2 (en) 2015-12-01
EP3019487A1 (en) 2016-05-18
US20150018373A1 (en) 2015-01-15
CA2917490A1 (en) 2015-01-15
TW201536767A (en) 2015-10-01

Similar Documents

Publication Publication Date Title
DOP2016000206A (en) FUSED HETEROCYCLIC COMPOUND
CL2017003404A1 (en) Antibacterial compounds
CR20160368A (en) HETEROCYCLIC COMPOUND
CL2017001987A1 (en) Compuestos derivados de 1-(het)arilsulfonil-pirrolidin-2-carboxamida, antagonistas de trpa1; composicion farmaceutica; y su uso en el tratamiento o profilaxis de dolor, artritis, asma, trastorno del oido interno, enfermedad inflamatoria del intestino, entre otras.
CO2017002170A2 (en) Combination therapy to treat a paramyxovirus
CL2016000153A1 (en) Glioxamide substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis b
ES2765949T8 (en) Therapy involving antibodies to claudin 18.2 for cancer treatment
DOP2016000337A (en) HETEROCICLICAL COMPOUNDS AND ITS USE AS GETMA-T INHIBITORS OF THE ORPHAN RECEPTOR RELATED TO RETINOID (ROR)
UY34566A (en) 1,4? DIHYDROPIRIMIDINES 4.4? DISUSTITUTED AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
UA118558C2 (en) Peptide compound
UY35774A (en) HETEROCYCLIC COMPOUND
AR096344A1 (en) ELASTOMER COMPOUNDS, MIXTURES AND METHODS TO PREPARE THE SAME
AR128158A2 (en) HETEROCYCLIC COMPOUND
CL2016001095A1 (en) Microporous zirconium silicate for the treatment of hyperkalemia.
CO2017003699A2 (en) Heterocyclic compound
CL2016001210A1 (en) Analogs of bicalutamide or (s) - bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal accumulation disorder or glycogenosis.
CL2017001025A1 (en) Compounds for use in anthelmintic treatment
CL2016001623A1 (en) Benzamide and nicotinamide compounds and methods for using them.
CL2016002879A1 (en) Pharmaceutical compositions for treating infectious diseases
UY35650A (en) HETEROCYCLIC COMPOUND
EA201591709A1 (en) 5-BROMED INDIRUBINES
UY37502A (en) CYCLIC DINUCLEOTIDE
CL2018000616A1 (en) Internal medical devices with guided surface wave energy
CL2015002612A1 (en) Antisense oligonucleototides for the treatment of cancer stem cells.
BR112016012248A2 (en) nephropathy treatment method

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211206